<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00704145</url>
  </required_header>
  <id_info>
    <org_study_id>1087/2007</org_study_id>
    <nct_id>NCT00704145</nct_id>
  </id_info>
  <brief_title>Optical Coherence Tomography Following Paclitaxel Eluting Stent Implantation in Multivessel Coronary Artery Disease</brief_title>
  <acronym>OCTAXUS</acronym>
  <official_title>A Prospective Optical Coherence Tomography Study on Completeness of Strut Coverage and Vessel Wall Response at 3-6 and 9 Months Following Paclitaxel Eluting Stent Implantation in Multivessel Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>A.O. Ospedale Papa Giovanni XXIII</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Case Western Reserve University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>A.O. Ospedale Papa Giovanni XXIII</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective Optical Coherence Tomography (OCT) study on the completeness of strut coverage
      and vessel wall response, at different time points (3-6-9 Months), following TAXUS Liberte
      stent implantation (staged procedures) in patients with multi vessel native coronary artery
      lesions
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Major concerns were addressed to the delayed healing process of drug-eluting stents in
      off-label indications. To date no studies have detailed the in-vivo completeness of DES
      coverage at different time points. The objective of this prospective study is to measure the
      completeness of strut coverage and vessel wall response (neointima disomogeneity, acquired
      late incomplete strut apposition) at different time points following paclitaxel-eluting stent
      implantation, in patients with multivessel disease treated with staged PCI procedures.
      Optical Coherence Tomography (OCT) that detects smaller degrees of stent strut coverage more
      accurately than IVUS will be used at different time point. Intravascular ultrasound (IVUS)
      will be performed as per normal practice at any index procedures and 9 months elective
      follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of uncovered and/or malapposed Taxus Libertè struts at different time point after the implant, as measured by OCT</measure>
    <time_frame>3-6-9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>% Incomplete apposition at different point of FU (3-6-9 months)</measure>
    <time_frame>3-6-9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of neointima disomogeneity around struts at different point of FU (3-6-9 months)</measure>
    <time_frame>3-6-9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OCT Neointima thickness overtime</measure>
    <time_frame>3-6-9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Target Vessel Failure (ID-TVF) rate at 12 months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjudicated MACE rate at 30 days and 12 months</measure>
    <time_frame>30 days and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Device, paclitaxel drug-eluting stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Taxus Libertè™ paclitaxel drug-eluting stent</intervention_name>
    <description>device:Taxus Libertè™ (Boston Scientific,Natick,MS)assessed at different time points after implant</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Taxus Libertè™ (Boston Scientific,Natick,MS)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Multivessel coronary artery disease (two or 3 VD) to be treated at 2 sequences (staged
             procedures) with paclitaxel-polymer eluting stents

          2. Native coronary artery disease with &gt;= 75% diameter stenosis

          3. Vessel size in between 2.5 and 3.5 mm.

          4. Written informed consent signed

        Exclusion Criteria:

          1. No suitable anatomy for OCT scan: (truly ostial , tortuous anatomy, very distal
             lesions or vessels larger than 3.75 in reference diameter).

          2. significant left main coronary artery disease,

          3. lesions in bypass grafts,

          4. acute myocardial infarction,

          5. poor cardiac function as defined by left ventricular ejection fraction ≤ 30%.

          6. allergy to aspirin and or clopidogrel/ticlopidine,

          7. Renal failure with creatinine value &gt; 2.5 mg/dl
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giulio Guagliumi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiovascular Department Ospedali Riuniti di Bergamo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ospedali Riuniti di Bergamo</name>
      <address>
        <city>Bergamo</city>
        <zip>24100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK, Virmani R. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol. 2007 Jul;27(7):1500-10. Epub 2007 May 17. Review.</citation>
    <PMID>17510464</PMID>
  </reference>
  <reference>
    <citation>Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, Gold HK, Virmani R. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation. 2007 May 8;115(18):2435-41. Epub 2007 Apr 16.</citation>
    <PMID>17438147</PMID>
  </reference>
  <reference>
    <citation>Park DW, Yun SC, Lee SW, Kim YH, Lee CW, Hong MK, Kim JJ, Choo SJ, Song H, Chung CH, Lee JW, Park SW, Park SJ. Long-term mortality after percutaneous coronary intervention with drug-eluting stent implantation versus coronary artery bypass surgery for the treatment of multivessel coronary artery disease. Circulation. 2008 Apr 22;117(16):2079-86. doi: 10.1161/CIRCULATIONAHA.107.750109. Epub 2008 Apr 14.</citation>
    <PMID>18413495</PMID>
  </reference>
  <reference>
    <citation>Briguori C, Colombo A, Airoldi F, Focaccio A, Iakovou I, Chieffo A, Michev I, Montorfano M, Bonizzoni E, Ricciardelli B, Condorelli G. Sirolimus-eluting stent implantation in diabetic patients with multivessel coronary artery disease. Am Heart J. 2005 Oct;150(4):807-13.</citation>
    <PMID>16209986</PMID>
  </reference>
  <reference>
    <citation>Rodriguez AE, Mieres J, Fernandez-Pereira C, Vigo CF, Rodriguez-Alemparte M, Berrocal D, Grinfeld L, Palacios I. Coronary stent thrombosis in the current drug-eluting stent era: insights from the ERACI III trial. J Am Coll Cardiol. 2006 Jan 3;47(1):205-7. Epub 2005 Dec 9.</citation>
    <PMID>16386687</PMID>
  </reference>
  <reference>
    <citation>Matsumoto D, Shite J, Shinke T, Otake H, Tanino Y, Ogasawara D, Sawada T, Paredes OL, Hirata K, Yokoyama M. Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography. Eur Heart J. 2007 Apr;28(8):961-7. Epub 2006 Nov 29.</citation>
    <PMID>17135281</PMID>
  </reference>
  <reference>
    <citation>Takano M, Inami S, Jang IK, Yamamoto M, Murakami D, Seimiya K, Ohba T, Mizuno K. Evaluation by optical coherence tomography of neointimal coverage of sirolimus-eluting stent three months after implantation. Am J Cardiol. 2007 Apr 15;99(8):1033-8. Epub 2007 Feb 23.</citation>
    <PMID>17437723</PMID>
  </reference>
  <reference>
    <citation>Yamaguchi T, Terashima M, Akasaka T, Hayashi T, Mizuno K, Muramatsu T, Nakamura M, Nakamura S, Saito S, Takano M, Takayama T, Yoshikawa J, Suzuki T. Safety and feasibility of an intravascular optical coherence tomography image wire system in the clinical setting. Am J Cardiol. 2008 Mar 1;101(5):562-7. doi: 10.1016/j.amjcard.2007.09.116. Epub 2008 Jan 10.</citation>
    <PMID>18307999</PMID>
  </reference>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2008</study_first_submitted>
  <study_first_submitted_qc>June 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2008</study_first_posted>
  <last_update_submitted>February 5, 2010</last_update_submitted>
  <last_update_submitted_qc>February 5, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2010</last_update_posted>
  <responsible_party>
    <name_title>Giulio Guagliumi</name_title>
    <organization>Ospedali Riuniti di Bergamo</organization>
  </responsible_party>
  <keyword>Drug Eluting Stents</keyword>
  <keyword>Percutaneous Coronary Interventions</keyword>
  <keyword>Optical Coherence Tomography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

